Table 6.
Summary of the available literature exploring the role of prophylactic treatment for stent-related event
| Disease | Ref. | Randomised | Type of stent | Total number of patients | Number of patients per arm | Treatment arm(s): Stent insertion plus…. | Investigation and result |
| Benign | Sciumè et al[21], 2004 | Yes | Plastic | 90 | 49/41 | Ursodeoxycholic acid and levofloxacin vs Ursodeoxycholic acid alone | Longer stent patency with lower cholangitis and admission rate. |
| (not blinded) | |||||||
| Katsinelos et al[22], 2008 | Yes | Plastic | 41 | 21/20 | Ursodeoxycholic acid vs Placebo | Common bile duct stones. No reduction in the bile duct stone size. | |
| (blinded) | |||||||
| Han et al[23], 2009 | No | Plastic | 28 | 28 | Ursodeoxycholic acid and terpene | Gallstones in elderly patients. Size of gallstones was reduced. | |
| Lee et al[24], 2011 | No | Plastic | 51 | 51 | Ursodeoxycholic acid | Gallstones in elderly patients. No benefit of adding Ursodeoxycholic acid. | |
| Nishizawa et al[25], 2013 | No | Plastic | 36 patients, 63 procedures | Non-randomised, two arms: 20/43 procedures | Ursodeoxycholic acid vs Observation | Bile duct stones. Longer patency time and reduction in gallstone size in the intervention cohort. | |
| Malignant | Ghosh et al[26], 19941 | Yes | Plastic | 70 | 31/39 | Ursodeoxycholic acid + antibiotic (ampicillin, metronidazole, ciprofloxacin) vs Observation | No differences in stent occlusion rate. |
| (not blinded) | |||||||
| Barrioz et al[27], 19941 | Yes | Plastic | 20 | Not specified | Ursodeoxycholic acid and norfloxacin vs Observation | Longer stent patency, prolonged median survival and shorter mean hospital stay. | |
| (not blinded) | |||||||
| Luman et al[28], 19991 | Yes | Not specified | 40 | 20/20 | Ciprofloxacin and rowachol vs Observation | Similar rate of obstruction and time to event. | |
| (not blinded) | |||||||
| Sung et al[29], 19991 | Yes | Plastic | 58 | Not specified | Ursodeoxycholic acid vs Observation | Similar rate of obstruction and time to event. | |
| (not blinded) | |||||||
| De Lédinghen et al[30], 20001 | Yes | Plastic | 62 | 33/29 | Ursodeoxycholic acid and norfloxacin vs Observation | Stopped after the interim analysis. No differences in stent patency. | |
| (not blinded) | |||||||
| Halm et al[31], 20012 | Yes | Plastic | 52 | 26/26 | Ursodeoxycholic acid and ofloxacin vs Ursodeoxycholic acid alone | Similar rate of obstruction and times to stent obstruction. | |
| (not blinded) | |||||||
| Chan et al[32], 20052 | Yes | Plastic | 94 | 50/44 | Ciprofloxacin vs Placebo | No differences in stent patency. Lower rate of cholangitis, but there was improvement in quality of life. | |
| (double blinded) |